Optima Research Boardman

Running trials

• Recruiting

  Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

  NCT07457918· Phase 3· Source

• Active, not recruiting

  Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

  NCT07246590· Phase 3· Source

• Active, not recruiting

  A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

  NCT07105488· Phase 2· Source

• Recruiting

  A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

  NCT06857942· Phase 4· Source

• Active, not recruiting

  Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

  NCT06846541· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity1 recruiting
• Psoriasis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

  NCT06921759· Phase 3· Source

• Completed

  Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

  NCT06588283· Phase 3· Source

• Completed

  A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

  NCT06588738· Phase 3· Source

• Completed

  Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

  NCT06144424· Phase 2· Source

• Terminated

  An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

  NCT05399368· Phase 2· Source